Indian Pharma Exports Surge In August: Laurus, Divi's Lead Growth
August pharmaceuticals export data for India points out that exports have grown both annually as well as monthly. Topping the charts is Laurus Labs Ltd., whose exports grew 94% year-on-year and 6% month-on-month. The export value for the month of August stood at $37.4 million.
The second in the list was Divi's Laboratories Ltd, which saw a 5% year-on-year jump in exports and a 32% month-on-month increase, which came at $89 million for August.
A major contributor for Divi's Laboratories was Sacubitril/Valsartan, which clocked $18.2 million, up 79% year-on-year and 21% month-on-month, with volumes doubling to 34.5 tonnes. Other key products included Dextromethorphan, Iopromide, Kisqali, Losartan, Naproxen, and Valsartan. New additions like Foslevodopa and a peptide coupling agent were also present.
Similarly, Neuland Laboratories Ltd. reported exports worth $12 million in August 2025, marking a massive 433% year-on-year growth and a 250% month-on-month surge.
On the flip side, Blue Jet Healthcare Ltd.'s exports stood at $3.9 million in August 2025, showing a decline from $8 million in August 2024 and $4.8 million in July 2025. The drop suggests some slowdown in overseas shipments or market demand.
Syngene recorded $7 million in exports for August 2025, down from $12 million in the same month last year and $8 million in July 2025.
The export data is important amid the ongoing tariff tensions between India and the United States. The Trump adminsitration has imposed a cumilative 50% tariff on Indian goods, 25% as a base tariff and an additional 25% as a penalty for India's continued purchase of Russian crude oil.
However, the pahrmaceutical sector has so far been exempt from these tariffs. Despite this, the situation remains uncertain, as Trumo has repeatedly threatened to impose a steep 200% tariff on pharmaceutical products. This looming threat continues to cast a shadow over India's pahrma exports to the US market.
-
We May Need Another Tukaram Mundhe To Fight Air Pollution | The Reason Why
Developers may install basic measures such as sprinklers and green nets, resume work, and continue violating rules when this equipment stops working.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.